The Delaware Supreme Court on Tuesday narrowly upheld a Delaware Court of Chancery ruling that denied a $50 million bonus payment to former investors in Calistoga Pharmaceuticals Inc. for partial European approval of a new blood-cancer treatment drug.
As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters.
Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss.
Tailored just for you. In your inbox. Every day.